Teplizumab

Chemical compound

Teplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody and the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people living with stage 2 type 1 diabetes.